Publication

[ACS Nano] Investigators developed FPC@S, a photodynamic immunomodulator that targeted the ECM, to improve the photodynamic immunotherapy for fibrotic breast cancer. FPC@S combined a tumor ECM-targeting peptide, a photosensitizer and an antifibrotic drug.

[Scientific Reports] The authors investigated whether the progression of liver fibrosis affects the prevalence of sarcopenia and incidence of decreased gait speed in older patients with chronic liver disease.

[Molecular Psychiatry] Scientists established a microglia-incorporated human cerebral organoid model carrying an SCN2A protein-truncating mutation identified in children with autism spectrum disorder. They found that human microglia display increased elimination of post-synapse in cerebral organoids carrying the SCN2A mutation.

[Communications Biology] Scientists investigated potential CMV pathogenetic mechanisms of fetal neural malformation using in vitro human cerebral organoids. Cerebral organoids were permissive to CMV replication, and infection dysregulated cellular pluripotency and differentiation pathways.

[Cytotherapy] Scientists sought to enhance the in vivo longevity of CAR-Vδ2 T cells by modulating ex vivo manufacturing conditions and selecting an optimal CAR costimulatory domain.

[eLife] Researchers implicated the ceramide synthases (CERS) 1 enzyme of the de novo sphingolipid synthesis pathway in the pathogenesis of age-related skeletal muscle impairment.